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Abstract
Background: Autism spectrum disorder (ASD) is an early-onset neurodevelopmental disorder with complex genetic
underpinning in its etiology. Copy number variations (CNVs) as one of the genetic factors associated with ASD have
been addressed in recent genome-wide association studies (GWAS). However, the significance of CNV has not been
well investigated in non-Caucasian ASD population.
Methods: To identify the pathogenic CNVs responsible for ASD in Han Chinese, we performed a segment-based
GWAS of CNV in 335 ASD cases and 1093 healthy controls using Affymetrix single nucleotide polymorphism (SNP)
array by focusing on case-specific CNVs. PARK2 was one of the important genes with several case-specific regions
overlapped on it. The findings were validated in the initial screen sample set and replicated in another sample set
by real-time quantitative PCR (qPCR).
Results: A total of six CNVs at 6q26 that spanned different exons of PARK2 were identified. The PARK2 expression
level was down-regulated at exon-dependent manner in cases with either deletion or duplication. The result revealed
that the gene function might be disrupted by exonic deletion and duplication. We also observed that the ASD case
with exonic duplication demonstrated a more severe interference of PARK2 expression and the clinical feature than the
ones with deletion at the exons 2–4 of the PARK2 gene.
Conclusions: Our finding provides evidence to support that CNVs affecting PARK2 function might contribute to
genetic etiology of a proportion of cases with ASD. The intriguing results of this work warrant further study on
characterizing the functional impact of various exonic CNVs on the PARK2 gene.
Trial registration: ClinicalTrials.gov NCT00494754
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Background
Autism spectrum disorder (ASD) is a common, early-
onset, long-term impairing neurodevelopmental disorder
with complex genetic underpinning in its etiology [1, 2].
Recent massive improvement in cytogenetic analysis en-
hanced the resolution and accuracy in detecting genomic
structural changes. Copy number variations (CNVs) are
the submicroscopic chromosomal deletions or duplica-
tions that affect more than 1000 base pairs of deoxyribo-
nucleic acid (DNA) sequence and alter normal gene
expression either by removing or adding the copies of a
gene or multiple genes [3, 4]. Accumulated evidence
from genome-wide CNV studies showed that ASD pa-
tients carried higher CNV burden than healthy controls
[5], and up to 10–20 % of ASD cases carried one or
more CNVs that contribute to the phenotypes [6].
Evidence from several studies of genome-wide analyses
of CNVs supports that rare CNVs, either de novo or inher-
ited, are associated with ASD [7–9]. Sebat et al.’s report of
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rare de novo CNVs in ASD using array comparative gen-
omic hybridization (aCGH) method [7] was supported by a
large-scale CNV study implemented by the Autism Gen-
ome Project (AGP) showing that the difference was mainly
contributed by the deletion-type CNVs [8]. Sander et al. re-
ported that duplications of 7q11.23, the region of Williams
Syndrome, were strongly associated with ASD and that
large de novo CNVs encompassing multiple genes were
more pathogenic in ASD (OR = 5.6, CI = 2.6–12.0, P =
2.4 × 10−7) [9]. Many of these loci/genes are relevant to the
process of neurotransmission [10–12], synapse formation
[10, 11], or protein ubiquitination [12]. Functional levels of
genes change with CNV (termed dosage sensors) may add-
itionally contribute to the etiology of ASD [10–12].
The PARK2 gene (OMIM*602544) is one of neurodeve-
lopmental genes that was originally discovered as one of
the causes of early-onset Parkinson disease (PD) [13] and
was subsequently reported to be associated with schizo-
phrenia [14], ASD [15], and attention-deficit/hyperactivity
disorder (ADHD) [16]. Glessner et al. (2009) identified de-
letions in the PARK2 gene in seven ASD patients, but
none in controls (P = 0.0047) [15]. Scheuerle et al. then
found two ASD patients with deletion and duplication of
PARK2 [17], and suggested that distinct phenotype in pa-
tients might be due to different CNV types in PARK2 and
the duplications may be equally causative for ASD [17].
Overall, these two studies provide some evidences to sup-
port PARK2 as a pathogenic gene of ASD [15, 17].
The majority of population-based studies of genome-
wide CNVs are about European ancestry but there is no
such study in the Asian population. Therefore, it is of
great importance to discover candidate CNVs that are re-
sponsible for ASD in Han Chinese. With the identification
of pathogenic CNVs, clinical diagnosis, and treatment for
ASD should be largely improved. Here, we report the
study using genome-wide association analysis of CNVs in
335 ASD cases and 1093 healthy controls of Han Chinese
ancestry in Taiwan. We identified a marginally significant
(not adjusted for multiple testing) ASD-associated gene,
PARK2, which was co-localized with a CNV region spe-
cific to ASD. The finding was further replicated in an in-
dependent sample set of 301 ASD cases and 301 healthy
controls. We also investigated how the expression of the
PARK2 gene was affected by the intragenic CNVs covering
various exons. Finally, we linked the clinical features of
ASD to the PARK2 CNVs and proposed the possible




A total of 335 Han Chinese patients with ASD, aged
9.39 ± 4.04 years (male 89.3 %) were recruited in Taiwan for
the genome-wide CNV comparison. They were clinically
diagnosed with autistic disorder according to the DSM-
IV and confirmed by using the Chinese version of the
Autism Diagnostic Interview-Revised (ADI-R) [18]. The
ADI-R interviews revealed the 335 probands scored
20.43 ± 6.12 in the “qualitative abnormalities in recipro-
cal social interaction” (cut-off = 10), 14.75 ± 4.32 in the
“qualitative abnormalities in communication, verbal”
(cut-off = 8), and 6.95 ± 2.47 in the “restricted, repetitive
and stereotyped patterns of behaviors” (cut-off = 3) cur-
rently if ages of 5 or younger or at their age of 4 to
5 years old with the typical symptoms if older than
5 years old (Table 2). They were recruited from Depart-
ment of Psychiatry of National Taiwan University Hospital
(NTUH), Chang Gung Memorial Hospital (CGMH),
Taoyuan, and Taoyuan Mental Hospital (TMH), Taiwan.
The patients diagnosed as fragile X, Rett’s disorder, or
other known chromosome/genetic disorders were excluded
from the study [19]. Their parents also reported about the
patients’ autistic behaviors on the Social Responsiveness
Scale (SRS) [18], and the cognitive functions assessed by
the Weschler Intelligence Scale for Children-3rd edition
(WISC-III) and Wisconsin Card Sorting Test (WCST).
The detailed description of the current and past ADI-R,
SRS, WISC-III, and WCST is provided in Table 2.
Healthy control cohort
One thousand ninety-three individuals (aged 68.07 ±
10.12 years, male 48.0 %) from the Han Chinese Cell and
Genome Bank (HCCGB) in Taiwan served as controls in
the CNV screening stage [20]. This control cohort re-
ceived physical check-up and questionnaire screening to
confirm that they did not have any physical condition.
The sample for replication
The ASD cohort for replication consisted of 301 inde-
pendent patients (aged 11.25 ± 5.47 years, male 88.4 %)
recruited from the same places as the initial ASD cohort
and received the same assessments. The ADI-R inter-
views revealed that the 301 probands for replication
scored 20.77 ± 6.28 in the “qualitative abnormalities in
reciprocal social interaction” (cut-off = 10), 15.87 ± 4.63
in the “qualitative abnormalities in communication, verbal”
(cut-off = 8), and 7.29 ± 2.65 in the “restricted, repetitive
and stereotyped patterns of behaviors” (cut-off = 3) cur-
rently if ages of 5 or younger or at their age of 4 to 5 years
old with the typical symptoms if older than 5 years old
(Table 2). The healthy controls for replication included 301
unrelated individuals (controls aged 19.59 ± 8.90 years,
male 64.1 %) recruited at NTUH, Taipei, Taiwan, either by
teachers’ referral or advertisement. Their lifetime and
current mental status were clinically evaluated by the cor-
responding author and confirmed by psychiatric inter-
views. Their family history of mental disorders was also
screened by clinical interviews.
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The study protocol was approved by the Research Ethics
Committee at each participating hospital and Academia
Sinica (National Taiwan University Hospital, 9561709027;
Chang Gung Memorial Hospital-Linkou, 93-6244; Taoyaun
Psychiatric Center, Ministry of Health and Welfare,
C20060905; Kaohsiung Chang Gung Memorial Hospital,
99-1548A3; Academia Sinica, AS-IBMS-MREC-91-10).
Written informed consent was obtained from the par-
ents and participants after the purposes and procedures
of the study were explained, and the voluntary partici-
pation was assured.
Genome-wide SNP genotyping and data analysis
Genomic DNA was extracted from the peripheral blood
of the ASD subjects and from EBV-transformed B cells
of the healthy controls by PUREGENE Genomic DNA
Purification Kit (Qiagen, Valencia, CA). The DNA sam-
ples were subjected to genotyping using Affymetrix
Genome-Wide Human SNP Array 6.0 (Affymetrix,
Santa Clara, CA) according to the manufacturer’s in-
structions and performed in the National Center for
Genome Medicine at Academia Sinica, Taipei, Taiwan (http://
ncgm.sinica.edu.tw/ncgm_02/index.html). The hybridization
intensities were captured by GeneChip Scanner 3000
(Affymetrix, Santa Clara, CA). CNVs were called using
Affymetrix Genotyping Console software v.4.1 (Affymetrix,
Santa Clara, CA). Genes overlapped with the CNV regions
were reported according to UCSC genes (NCBI37/hg19).
Details on genotyping and sample quality control,
the procedures for CNV detection and extraction,
and the global CNV burden measurement are pro-
vided in Additional file 1: Figure S1 and Additional
file 1: Table S1.
Case-specific CNV locus
The segment-based association analysis was conducted
using Python (https://www.python.org). CNV regions
on autosomes were analyzed in all samples while CNV
regions on sex chromosomes were analyzed in male
samples only. Duplication-type CNV and deletion-type
CNV were treated as different CNVs. CNV regions
identified in each individual were stacked and parti-
tioned at each unique start and stop site for the CNV
regions to form non-overlapping genomic segments for
frequency calculation. A total of 38,660 individual auto-
somal CNV regions formed 7883 CNV segments, and a
total of 1999 individual sex-chromosome CNV regions
identified in male samples formed 615 CNV segments.
CNV segments that were detected only in cases were
defined as case-specific CNVs. The case-specific CNV
segments that were flanking to each other or belonged
to the same gene were manually merged into case-
specific CNV loci for report.
Validation and replication analysis of CNVs
The case-specific CNVs were validated by SYBR-Green
based genomic quantitative PCR (qPCR) using ABI
StepOne Plus system (Applied Biosystems, Forster, CA).
Primer pairs specific to various exons of the PARK2 gene
(NM_004562), the FARP2 locus on chromosome 2 and
the GAPDH locus on chromosome 12 were used as in-
ternal controls for qPCR. A total of 10 ng of genomic
DNA was used in each PCR reaction, which was con-
ducted in triplicate for both target locus and internal
control loci. The fold change of copy number was calcu-
lated by comparative Ct method. The relative fold
change to normal subject was determined as 2−ΔΔCt.
Samples with fold change greater than 1.25 (duplication)
or less than 0.75 (deletion) are considered to have a copy
number change.
At replication stage three additional pairs of primers
were designed to cover exons 1, 2, and 4 of the PARK2
gene, respectively. The information of these primers is
listed in Additional file 1: Table S2.
Gene expression analysis
Total ribonucleic acid (RNA) was extracted from periph-
eral blood cells by RNeasy Miniprep Kit (Qiagen system)
following the manufacturer’s instructions. Of purified
RNA sample, 1.2 μg was used for complementary DNA
(cDNA) synthesis by using High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). The cDNA prod-
uct was subjected to SYBR-Green based qPCR by ABI
StepOne Plus system (Applied Biosystems) for PARK2
expression analysis. GAPDH was used as an internal con-
trol. A 20-fold dilution of cDNA product was used in each
PCR reaction in triplicate for both target gene and internal
control gene. The information of the primers is listed in
Additional file 1: Table S2. The probands, PARK2 CNV
carriers in the families, non-carriers in the families, and
four unrelated controls without PARK2 CNV were assayed
individually. Relative fold change of PARK2 exon expres-
sion was calculated by 2−ΔΔCt method using individuals
without PARK2 CNV as expression baseline.
Statistical analysis
Two-tailed Fisher’s exact test was performed to evalu-
ate the associations of individual CNV segments and
case-specific CNV loci with ASD. Student t test was
used to compare the messenger ribonucleic acid
(mRNA) expression level between the two groups.
Results and discussion
Case-specific CNV loci
The present study focused on the case-specific CNV seg-
ments, which were detected in at least one case but none in
healthy controls from the screening stage (Additional file 1:
Figure S2). The flanking case-specific CNV segments with
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the same type of CNV were merged into CNV loci for
statistical analysis and annotation. A total of 461 case-
specific CNV loci overlapped with genes were identified
(Additional file 1: Table S3). These case-specific CNV
loci consisted of 196 deletions (42.5 %) and 265 dupli-
cations (57.5 %), and most of them were individually
rare (<1 % of cases). These CNV loci spanned 0.3 to
4623.3 kb (average CNV locus size: 143 kb) and over-
lapped with exons of a single gene to more than 40 genes.
Among the identified case-specific CNV loci, 17 were lo-
cated in six chromosomal regions of the well-known ASD-
associated CNV, 1q21.1, 15q11.2-13.1, 15q13.3, 16p11.2,
22q11.21, and 22q13.33 (Additional file 1: Table S4).
Our findings that there were case-specific CNVs lo-
cated in these 17 ASD-associated loci replicate those
findings of pathogenic CNV loci from previous studies
[5, 7–9, 15, 21–24]. In addition to the known CNV loci as-
sociated with ASD, we identified 17 marginally significant
(not adjusted for multiple testing) case-specific CNV
loci at which duplication and deletion were detected
in at least four cases (patient frequency (Fpatient) > 1 %;
P < 0.01) (Table 1). Genes overlapped with these case-
specific CNV loci could be candidate pathogenic genes for
ASD (Table 1). Among them, the PARK2 gene is the only
one that has been reported to be associated with ASD.
Validation and replication analysis of CNVs at the PARK2
locus
A total of four exonic CNVs within the PARK2 locus
were identified in ASD cohort at the initial screening
stage (three deletions, one duplication, Fpatient = 1.19 %).
Each of them overlapped with different parts of the
PARK2 gene and was categorized into three coverage re-
gions: A, B, and C (Fig. 1). With the three regions as
baits, two duplications within the A region were identi-
fied in two healthy controls (Fcontrol = 0.18 %) (Fig. 1).
Nevertheless, both of them were shorter, and only one
overlapped with the exon 3 of PARK2. The prevalence of
CNVs at the entire PARK2 locus remained significant in
ASD cases compared to the controls (P = 0.030). Copy
number status at the PARK2 locus in the initial samples
was validated by genomic qPCR (Fig. 2a and Additional
file 1: Figures S3 and S4).
CNV detection in the replication cohort focused on
exons in regions A, B, and C by using genomic qPCR
with the same primer pairs used for validation. We de-
tected two exonic CNVs (one deletion, one duplication,
Fpatient = 0.66 %) at the A region carried by two ASD
cases (Fig. 2b) while no exonic CNVs were detected in
controls. The probability that the CNVs identified in the
two cases might extend to adjacent exons was tested by
using genomic qPCR with primer pairs specific to exons
1, 2, 4, and 5, respectively. The results showed that
U2650 indeed had a deletion spanning exons 2–4 (Figs. 1
and 2c). The PARK2 transcript missing exons 2–4 is
predicted to result in frameshift and lead to a nonsense
mutation at codon 9 in the mutant mRNA. U2890 had a
duplication overlapped with exons 2–3 (Figs. 1 and 2c).
Taken together, the frequency of exonic CNVs at the
PARK2 locus was significantly greater in ASD cases (6/
Table 1 Selected case-specific copy number variation loci
Locus Position (start–end) Gene Gain_case Loss_case Gain_control Loss_control
1p36.21 13377035–13538299 PRAMEF8,PRAMEF9,PRAMEF13,
PRAMEF19,PRAMEF16,PRAMEF20
6 0 0 0
1p36.13 17262235–17295200 CROCC 4 0 0 0
1q25.1 174802140–174802829 RABGAP1L 0 4 0 0
2p11.2-p11.1 91801473–92136779 LOC654342,Mir_544,GGT8P,ACTR3BP2 7 0 0 0
3p12.3 75639495–75930920 MIR1324,FLJ20518,LOC401074,ZNF717,MIR4273 10 0 0 0
3q22.1 129806912–129914958 ALG1L2, FAM86HP 27 1 0 0
4p16.1 9486075–9744591 MIR548I2,AB059369 8 1 0 0
4p16.3 3885796–4190560 DQ584669,FAM86EP,BC042823,OTOP1 14 0 0 0
4q13.2 69371991–69410211 UGT2B15, UGT2B17 0 5 0 0
6q26 162187125–162680305 PARK2 1 3 2 0
8p23.1 12542721–12587390 LONRF1,MIR3926-1,MIR3926-2 5 0 0 0
9q13 68176154–68683835 AK308561,BC080605,LOC642236 17 0 0 0
12p13.31 8378239–8536600 LINC00937, FAM86FP, FAM90A1 5 0 0 0
14q11.2 24429298–24513905 DHRS4,DHRS4L2,DHRS4L1 1 11 5 10
19q13.42 55360538–56717229 >60 genes 4 0 0 0
21q11.2 14456404–14594223 ANKRD30BP2 8 1 0 0
22q11.23 24396802–24404830 GSTTP2 0 4 0 0
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636) than in controls (2/1394, P = 0.014, Additional file 1:
Table S5). Of note, five probands revealed that the PARK2
CNVs were paternally inherited (Fig. 2a, b, d) except that
the DNA sample was not available from the father of
U2890. We could only confirm that the duplication was
not inherited from the mother (Fig. 2b). In addition, we ob-
served that the sister of U2650, who had the same PARK2
exonic deletion, did not demonstrate any autistic feature.
In contrast, the father of U1984 (duplication) was clinically
diagnosed with high-functioning autism (Fig. 2a, d).
PARK2 expression analysis
To assess how this exonic CNV affected gene function,
we performed quantitative RT-PCR (qRT-PCR) to com-
pare the mRNA expression level of PARK2 in individuals
with and without exonic CNV. Family U1984 and Family
U2650 consented to this experiment and were found to
possess two different types of CNVs covering exon 3 and
exon 4 which belonged to the A region at the PARK2
locus. We used two primer pairs specific to the CNV-
affected regions (exons 3–4 and exons 4–5), and two
primer pairs specific to the CNV-unaffected regions
(exons 6–7 and exons 9–11) for the quantification of
PARK2 mRNA expression, respectively. We observed a
fold change of 0.61 for exons 4–5, 0.48 for exons 6–7,
and 0.58 for exons 9–11 in the proband and the father
of Family U1984 when compared with unaffected
controls (P = 0.014, P = 0.026, and P = 0.01, respectively).
In contrast, no difference in the expression level of
exons 3–4 was detected (Fig. 3a).
We observed a fold change of 0.46 for exons 3–4 and
0.56 for exons 4–5 in the proband and deletion-carriers
of Family U2650 when compared with those of un-
affected controls (P = 0.014 and P = 0.004, respectively).
However, no significant difference of the expression level
of exons 6–7 or exons 9–11 between controls and
deletion-carriers was found (Fig. 3b).
There were three transcript variants of the PARK2
gene according to the RefSeq Gene database (Fig. 3c).
The exon-dependent change of PARK2 expression
level in the probands and carriers of Family U1984
and Family U2650 implies that both the wild-type and
mutant genomic copy of the PARK2 gene were
expressed. Based on the qRT-PCR result, it is likely
that the transcript variant 1 from the wild-type gen-
omic copy (Fig. 3c) and mutant transcript consisting
of exons 1–4 resulted from the mutant genomic copy
(Fig. 3d) were expressed in the proband and the
father of Family U1984. Likewise, the transcript vari-
ant 1 from the wild-type genomic copy (Fig. 3c) and
mutant transcript missing exons 2–4 resulted from
the mutant genomic copy (Fig. 3e) were suspected to
be expressed in the individuals of Family U2650 with
deletion of exons 2–4.
Fig. 1 Genomic location of CNVs at the PARK2 locus. Red bars and dark blue bars represent deletions and duplication, respectively, at the PARK2
gene detected in the cases. Light blue bars represent duplication identified in healthy controls. Transcript and genomic coordinates corresponds
to human genome Build 37 (hg 19). The A region overlaps with exons 3–4, which corresponds to the UBL and RING0 domain of the Parkin
protein. The B region overlaps exon 5, which corresponds to the RING0 domain of the Parkin protein. The C region overlaps with exons 6–7,
which corresponds to the RING0 and RING1 domain of the Parkin protein
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Fig. 2 (See legend on next page.)
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Clinical features of patients with PARK2 exonic CNVs
Pedigrees of these six families with male probands are
illustrated in Fig. 2d. The age at recruitment (6–21 years
old), clinical diagnosis, intelligence quotient (IQ) profiles
(full-scale IQ, 83-117), subscores of the ADI-R and SRS,
and WCST indexes of the five probands (except U2890)
are summarized in Table 2. Based on the clinical as-
sessment, all the parents of the six patients did not
have ASD except that the father of U1984 had high-
function autism (HFA) and the father of U1469 had
autistic trait assessed by the autism-spectrum quotient
(AQ) (Additional file 1: Table S6).
Both U1984 and U2650 were found to have CNVs at
the A region of PARK2 with different exonic CNV
patterns (duplication/deletion). U1984 was born in a
family with unrelated parents and had an unaffected
typically developing younger brother. He presented
speech delay (two words and simple sentence at age 4),
stereotyped and socially inappropriate speech, abnor-
mal social reciprocity, and restricted/repetitive behav-
iors and interests. He demonstrated severe autistic
symptoms compared to U2650 in a wide range of
autistic features at his age of 4–5 years old and current
status (Table 2). He suffered from the first attack of
absence seizure at his age of 2.5 years old but no anti-
epileptic drug was used. U1984 had a relatively lower
IQ profile (Full-IQ = 83) than the other four probands,
and his performance of WCST showed increased
(See figure on previous page.)
Fig. 2 Detection of CNVs at the PARK2 locus by genomic qPCR. a SYBR-based qPCR assays were performed to validate exonic CNVs at the PARK2
locus in the cases and the family members. Data is presented as mean ± SD. b Additional two ASD cases with CNV at exon 3 of the PARK2 locus
were detected. c Copy number changes of five exons (exons 1 to 5) of the PARK2 gene were measured to determine the spanning of the CNV
region in cases U2650 and U2890. EX exon. Data is presented as mean ± SD. d Pedigrees of probands with PARK2 exonic CNVs. Arrows indicate
the proband in each family. N/A genomic DNA was not available, del deletion, dup duplication. Exons involved are determined by genomic qPCR
Fig. 3 Expression analysis of PARK2. The expression level of PARK2 transcript was detected using four primer pairs specific to EX3-4, EX4-5, EX6-7,
and EX9-11, respectively. Decreased expression level of specific PARK2 exons was observed in (a) case group of Family U1984 and (b) case group
of Family U2650 (*P < 0.05, **P < 0.01). c Alternative splicing of PARK2 gene produces three known transcript variants (transcript variant 1: grey,
transcript variant 2: blue, transcript variant 3: red) according to RefSeq Gene. Arrows on the top of the gene locus indicate the primer pairs used
for expression detection. d The proposed genomic DNA rearrangement and PARK2 mutant transcript (purple) in the proband U1984 with duplication
of EX3-4 on PARK2 based on the result of qRT-PCR. The frame was drawn in orange to represent the EX3-4 duplication. e The proposed PARK2 mutant
transcript (green) in the proband U2650 with deletion of EX2-4 on PARK2 based on the result of qRT-PCR
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Table 2 Clinical features of male probands with PARK2 exonic CNV






Age (year) of diagnosis 6 2 8 7 8 – – –
Age (year) of recruitment 6 15 10 7 10 21 9.39 ± 4.04 10.66 ± 5.36
Clinical diagnosis Autism HFA HFA Autism HFA Autism – –












Inheritance Paternal Paternal Paternal Paternal Paternal Unknown
Speech delay N Y Y Y N –










10/13 5/12 8/14 13/16 9/13 – 11.48 ± 3.83/14.75 ± 4.32 13.10 ± 4.59/15.87 ± 4.63
Restricted, repetitive,
stereotyped patterns of
behaviors (cut-off = 3)
7/7 2/5 3/5 6/10 4/6 – 5.43 ± 2.48/6.95 ± 2.47 5.61 ± 2.46/7.29 ± 2.65
Abnormality of development
evident at or before 36 months
(cut-off = 1)
2 5 2 4 1 – 3.44 ± 1.53 3.18 ± 1.63




42 (84.81) 42 (89.91) 34 (74.08) 49 (92.51) 17 (56.50) – 37.28 ± 14.13 41.04 ± 15.07
Stereotyped behaviors/interest
(score 0–39)
24 (83.74) 24 (90.13) 17 (70.30) 27 (89.47) 10 (57.17) – 18.88 ± 7.00 20.04 ± 7.42
Social awareness (score 0–33) 24 (65.07) 28 (69.01) 23 (62.20) 21 (60.23) 16 (51.36) – 21.70 ± 4.97 21.85 ± 5.45
Social emotion (score 0–24) 16 (71.43) 15 (72.56) 15 (69.22) 14 (66.97) 7 (51.44) – 11.45 ± 4.55 12.64 ± 4.76
Total score (score 0–180) 106 (83.32) 109 (88.77) 89 (72.90) 111 (85.76) 50 (55.25) – 89.24 ± 25.84 95.57 ± 28.56
Intelligence quotient (IQ)
Verbal IQ (range) 117 122 107 84 121 – 95.08 ± 23.79 (44–148) 94.80 ± 23.79 (40–145)












Table 2 Clinical features of male probands with PARK2 exonic CNV (Continued)
Full–scale IQ (range) 105 109 102 83 117 – 94.85 ± 22.55 (40–148) 93.56 ± 23.14 (40–141)
Wisconsin Card Sorting Test (WCST) (%)
Total errors 63 (4 %) 35 (21 %) 19 (84 %) 48 (14 %) 16 (92 %) – 44.11 ± 26.61 39.75 ± 25.25
Perseverative response 34 (14 %) 20 (21 %) 6 (96 %) 55 (2 %) 8 (88 %) – 27.32 ± 25.29 25.95 ± 26.15
Perseverative errors 30 (13 %) 19 (18 %) 6 (97 %) 43 (3 %) 8 (87 %) – 23.51 ± 19.31 22.23 ± 19.95
Nonperseverative errors 33 (4 %) 15 (32 %) 13 (53 %) 5 (92 %) 8 (82 %) – 20.60 ± 15.71 17.60 ± 12.07
Conceptual level responses 18 (4 %) 53 (18 %) 77 (82 %) 39 (16 %) 81 (91 %) – 58.44 ± 23.96 59.52 ± 21.03
Categories completed 2 (>16 %) 6 (>16 %) 6 (>16 %) 1 (>16 %) 6 (>16 %) – 4.12 ± 2.03 4.39 ± 2.02
CNV copy number variation, ADI-R the ADI-R interviews revealed the 636 patients scored 20.7 ± 6.5 in the “qualitative abnormalities in reciprocal social interaction” (cut-off = 10), 15.2 ± 4.7 in the “qualitative abnormalities
in communication, verbal” (cut-off = 8), and 7.0 ± 2.7 in the “restricted, repetitive, and stereotyped patterns of behaviors” (cut-off = 3), SRS the Chinese version of the Social Responsiveness Scale (60 items; score 0 (never true) - 3
(almost always true); total scores can range from 0 to 180) and the t score was generated by comparing to Taiwanese norm, HFA high function autism. WCST percentile≤ 10 %: poor performance, percentile 11~90 %: normal range,












perseverative response and errors, suggesting an im-
paired cognitive flexibility.
U2650 (deletion in PARK2), diagnosed as HFA, showed
no speech delay and less severe autistic symptoms
assessed by the ADI-R and SRS compared to the other
probands. His key features were socially inappropriate
communication and interactions, a lack of non-verbal
communication (e.g., eye contact, gesture, or distal index
pointing), and stereotyped pattern of interests, verbal rit-
uals, and schedules (Table 2). He demonstrated above
average IQ profiles (Full-IQ = 117) and did not have
impaired WCST performance. Although his sister carries
the same deletion in PARK2, the clinical assessment and
parental reports revealed her as a typically developing
child without any autistic symptom.
U1469, who carried an exonic deletion spanning exons
6–7 of PARK2, showed abnormal social reciprocity and
communication, neither sharing nor comforting, same-
ness in a wide range of behaviors, and unusual sensory
interests, which had been clearly noted before 3 years
old. Despite IQ profiles within the normal range, he
demonstrated impaired cognitive flexibility as assessed
by the WCST (Table 2). His PARK2 deletion was inher-
ited from his father, who showed some autistic trait such
as restricted interests, social inflexibility, and concrete
thought based on clinical assessment.
Both U1290 and U1859, diagnosed with HFA, had ex-
onic deletions spanning exon 5 of PARK2 (Table 2).
U1290 exhibited speech delay and started to combine two
words to make simple sentences until age 4; U1859 was
observed to have speech delay. They both had difficulty in
offering comfort to other people, engaging reciprocal so-
cial interactions, developing peer relationships, and imitat-
ing behaviors/action. The cognitive assessments of these
two probands did not reveal any abnormal results, but
U1859 revealed better WCST performance than U1290.
In this study, we focused on the case-specific CNVs ra-
ther than rare CNVs (<1 % frequency in total samples).
With this approach, we have sufficient power to catch
variants that exist only in ASD cases without losing any
important CNVs that have >1 % frequency. For example,
we found that the CNVs on chromosome 3q22.1 and
9q13 were presented at more than 1 % of frequency in
the total samples, but indeed were contributed only from
the cases (Table 1). Among the candidate genes over-
lapped with case-specific CNV loci, we focused on PARK2,
which has been known to be associated with ASD [15],
other neuropsychiatric disorders [13, 14, 16], and neuronal
functions in Caucasian population [25–28]. With two in-
dependent sets of case-control cohorts, we demonstrated
that the frequency of CNVs affecting PARK2 gene was
significantly higher in individuals with ASD compared to
controls (0.94 vs. 0.14 %, P = 0.014). Our findings strongly
suggest that CNVs at the PARK2 locus contribute to the
susceptibility of ASD in the Han Chinese population res-
iding in Taiwan. Of note, in the present study, there were
12 people who carried PARK2 CNVs from six families,
and seven of them were diagnosed with ASD, and the
PARK2 CNVs were often transmitted by unaffected par-
ents. The study of Icelandic population by Huttenlocher
and her colleagues demonstrated that the frequency of
heterozygous PARK2 CNVs was significantly higher in pa-
tients with Parkinson’s disease (PD) compared to controls
(OR = 1.69, P = 0.03) [29]. They concluded that heterozy-
gous carriers for exonic CNVs in PARK2 were at an
increased risk of developing PD. On the other hand, their
results also clearly demonstrated that there was a signifi-
cant proportion of individuals who carried heterozygous
PARK2 CNV who did not develop PD after age 65. There-
fore, based on their results, the penetrance for PD from
heterozygous CNVs in PARK2 would not be high. In this
report, the six indexed ASD cases, one affected father, and
the five unaffected carriers were all heterozygote of
PARK2 CNVs. Therefore, we speculate that the pene-
trance for ASD from heterozygous PARK2 CNV was not
high, either.
Our result that PARK2 is strongly suspected as a can-
didate gene for ASD is in line with Glessner’s observa-
tion [15]. However, the enriched CNVs in their study
were located at the intronic region and might not dir-
ectly influence the expression or function of the gene
[15]. Moreover, a comprehensive study of PARK2
showed that CNVs involving PARK2 were identified in
1 % of control subjects, and CNVs involving exons 2–4
were well-tolerated while exons 5–12 were not. Kay and
colleagues suggested that the mutations affecting exons
5–12, the coding region for highly conserved function
domains of Parkin, might be more deleterious [30]. This
suggestion may explain our findings on the clinical fea-
tures of four probands: U1469 (exons 6–7) had more se-
vere autistic symptoms than U1290 and U1859 (exon 5),
and U2650 (exons 2–4) had less severe autistic symp-
toms than other probands.
The PARK2 transcript missing exons 2–4 is predicted
to result in a frameshift and lead to a nonsense mutation
at codon 9 in the mutant mRNA. Similar to the predic-
tion, we observed that the mRNA expression levels in
U2650 and carriers with EX2-4 deletion were changed in
an exon-dependent manner: decreased by half in the
CNV-affected exons but was not affected in the CNV-
unaffected exons, suggesting that a mutant PARK2 tran-
script without EX2-4 is generated (Fig. 3e). However,
surprisingly, nonsense-mediated decay did not occur
with this transcript. We speculate that the mutant tran-
script would be translated into a non-functional protein,
and the individual carrying this mutation has half dose
of functional PARK2 proteins. However, U2650 was one
of the less severe autistic symptoms of patients with
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PARK2 exonic CNV in this study, supporting that intra-
genic deletion involving exons 2–4 might be less patho-
genic for autistic symptoms.
On the other hand, U1984 who possessed a duplication-
type CNV encompassing exons 3–4 manifested more
severe autistic symptoms and worse cognitive function
than other patients with deletion-type CNVs. The distinct
phenotypes might be due to the different dosages of CNV
(duplication/deletion). Interestingly, the duplication was
partially overlapped with the findings from Scheuerle et al.
[17]. They reported a male who had a duplication encom-
passing exon 2 on PARK2 and revealed cognitive impair-
ment and global developmental delay with particular
problems on social and language skills [17]. Later, Marinai
and colleagues described similar situation, and their obser-
vations also supported the idea that duplication of the
PARK2 gene possibly plays a role in the pathology of devel-
opmental anomalies [31]. Those probands with duplica-
tions from Scheuerle et al’s and Marinai et al’s studies seem
to have similar clinical features with U1984 who suffered
from language delay and epilepsy. Intriguingly, we observed
down-regulation of EX4-5, EX6-7, and EX9-11 but normal
expression of EX3-4 on the mRNA level in proband U1984
and the carrier with duplication of EX3-4 on PARK2 in the
family. Based on the expression analysis, we speculate that
the copy number gain may lead to a splicing error; hence, a
shorter transcript lacks most of the 3′ end of the PARK2
mRNA (Fig. 3d). Whether the mutant transcript would
interfere with the normal PARK2 transcript (Fig. 3c) is not
clear. Nevertheless, the observation that U1984 had the
most severe ASD and cognitive impairment among the
probands with CNVs on PARK2 might imply that duplica-
tion of PARK2 EX3-4 has effect beyond decreasing PARK2
protein. These observations warrant further investigations
of pathogenic mechanism of PARK2 CNVs.
The PARK2 gene encodes Parkin, a RING-between-
RING E3 ubiquitin ligase functioning in the covalent
attachment of ubiquitin to specific substrates for pro-
teasomal degradation [32]. The structure of human
Parkin ligase has been reported in exquisite detail
[33–35]. Parkin is structurally tight packed by two
hydrophobic interactions, which keep Parkin in an auto-
inhibited conformation. A study showed that mutations
(M192A, F463A, and A398T) at the RING0-RING2
domain and linker helix could disrupt the interface and
lead to autoubiquitination of PARK2 (the “opening” struc-
ture) in cell [27]. The deletion encompassing exon 5 of
the PARK2 gene in U1290 and U1859 is predicted to re-
sult in in-frame deletion which leads to losing a part of
RING0 domain. This may lead to a conformational change
of Parkin protein and activation of the autoubiquitination.
The deletion encompassing exons 6–7 of the PARK2 gene
in U1469 is predicted to cause the Glu207Leu amino acid
change and lead to nonsense mutations at the 213th
codon of the mutant mRNA (Additional file 1: Figure S3).
We speculate that this intragenic deletion might largely
influence the biological functions of Parkin owing to trun-
cated protein lacking the C-terminal part. However, we
were unable to obtain the RNA sample from the probands
with deletions comprising exon 5 or exons 6–7 for gene
expression analysis. Further studies to investigate how
these deletions affect Parkin at the transcript level, protein
level, and function level are needed to reveal PARK2
CNV-mediated ASD pathogenesis.
Literature documents that Parkin plays a fundamental
role in mitochondrial functions. The PINK1-Parkin
pathway is one of well-studied pathways of mitophagy.
Mutations in PINK1 and PARK2 are associated with
neurodegeneration in Parkinson Disease [13, 25] and
are hypothesized to impair the protein function and
hence result in insufficient mitochondrial clearance and
subsequent aggregation. In addition, a recent study has
also shown that loss of Parkin function suppressed
mitochondrial biogenesis through accumulation of
Parkin-interacting substrate (PARIS), a transcriptional
repressor of PGC-1a, which stimulates mitochondrial
biogenesis as an activator [26]. Taken together, these
evidences strongly suggest that Parkin with a loss-of-
function mutation may lead to abnormal mitochondrial
biogenesis and clearance, which is considered to link to
the pathology of ASD [36]. In addition, Parkin protein
is abundantly expressed in the human brain, including
the frontal lobe cortex, substantia nigra, putamen, and
locus coeruleus [28]. Therefore, with the observations
reported in this study, we suspect that the ASD-
associated PARK2 CNV might contribute to the patho-
genesis of ASD through affecting mitochondria in par-
ticular brain region (e.g., frontal lobe) in a proportion
of children.
Conclusions
In summary, our study indicated that PARK2 could
be a pathogenic gene associated with ASD in the Han
Chinese population. With limited samples, we also
observed that exonic duplication might result in a
more severe interference of PARK2 expression and
the clinical feature than deletion at the A region
(exons 2–4) of the PARK2 locus. The intriguing
results of this work warrant further study on charac-
terizing the functional impact of various exonic CNVs
on the PARK2 gene and its role in mitochondria mal-
function in the brain of patients with ASD.
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